Enliven Therapeutics, Inc. $ELVN Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 18.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 80,072 shares of the company’s stock after purchasing an additional 12,597 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Enliven Therapeutics were worth $4,064,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at approximately $38,000. BNP Paribas Financial Markets lifted its holdings in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics in the fourth quarter worth approximately $83,000. Quantbot Technologies LP grew its position in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the period. Finally, State of Wyoming acquired a new stake in Enliven Therapeutics during the second quarter worth $96,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director directly owned 87,373 shares in the company, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the sale, the chief financial officer directly owned 40,036 shares in the company, valued at $2,345,308.88. This represents a 13.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 186,849 shares of company stock worth $10,998,857 in the last three months. 3.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. JonesTrading lifted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. HC Wainwright increased their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Barclays initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective on the stock. Finally, Stifel Nicolaus increased their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Enliven Therapeutics Stock Down 3.2%

NASDAQ:ELVN opened at $57.45 on Thursday. The stock’s fifty day moving average is $56.18 and its two-hundred day moving average is $45.00. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32. The stock has a market capitalization of $4.21 billion, a price-to-earnings ratio of -34.40 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.